8-K Announcements
6Material company update
Jan 28, 2026·SEC
Material company update
Jan 16, 2026·SEC
Material company update
Dec 29, 2025·SEC
Repare Therapeutics Inc.(RPTX)Earnings, Financials & Key Ratios
RPTX•NASDAQ
$2.65
Price updated Jun 20, 2026
AboutRepare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.Show more
- Revenue$53M+4.6%
- EBITDA-$92M+19.8%
- Net Income-$85M+9.7%
- EPS (Diluted)-2.00+10.3%
- Gross Margin74.98%+1.2%
- EBITDA Margin-171.29%+23.4%
- Operating Margin-174.88%+23.1%
- Net Margin-158.37%+13.7%
- ROE-46.63%-22.2%
RPTX Price & Volume
Repare Therapeutics Inc. (RPTX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Milestone Volatility Masks Structural Liquidity Risks
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical milestone funding dependency
Key Thesis Takeaways
- Repare Therapeutics remains a high-risk, clinical-stage biotechnology firm whose valuation is tethered to the success of its SNIPRx platform and the ability to secure future partnership milestones.
- The company's financial profile is characterized by extreme revenue lumpiness, evidenced by a shift from $52.4M in 2024Q1 revenue to periods of zero revenue, which complicates long-term forecasting.
- Investors should remain cautious as the erosion of the cash position to $72.8M in 2025Q3, coupled with a massive accumulated deficit of -$461.3M, suggests a high probability of future dilutive financing to sustain ongoing clinical development.
Verdict Logic
the company's reliance on intermittent milestone payments and a declining cash balance of $72.8M in 2025Q3 create significant uncertainty regarding its ability to fund long-term clinical trials without further equity dilution.
RPTX Growth Metrics
Repare Therapeutics Inc. (RPTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years91.62%
TTM-82.16%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.1%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.5%
Return on Capital
10 Years-44.82%
5 Years-32.07%
3 Years-34.65%
Last Year-51.1%
RPTX Recent Earnings
Repare Therapeutics Inc. (RPTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (56%)
Q2 2026Latest
Mar 2, 2026Metric
Actual
Est
EPS
$0.67-131.0%
$0.29
Rev
—
$3M
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.08+121.6%
$0.35
Rev
$12M+364.8%
$3M
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$0.39+30.4%
$0.56
Rev
$250,000-85.0%
$2M
Q2 2025
May 13, 2025Metric
Actual
Est
EPS
$0.71-9.2%
$0.65
Rev
$5M+200.0%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 2, 2026 | $0.67vs $0.29-131.0% | —vs $3M |
| Q4 2025 | Nov 14, 2025 | $0.08vs $0.35+121.6% | $12Mvs $3M+364.8% |
| Q3 2025 | Aug 8, 2025 | $0.39vs $0.56+30.4% | $250,000vs $2M-85.0% |
| Q2 2025 | May 13, 2025 | $0.71vs $0.65-9.2% | $5Mvs $2M+200.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Repare Therapeutics Inc. (RPTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.65 | $114.24M | -1.33 | 4.58% | -158.37% | -46.63% | — | |
| $182.08 | $38.71B | -30.60 | — | — | -83.22% | — | |
| $1.17 | $62.4M | -0.79 | — | — | -68.98% | — | |
| $115.07 | $6.73B | -28.27 | -79.35% | -1027.25% | -55.42% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $9.62 | $237.77M | -2.80 | -100% | — | -73.16% | — |
Compare RPTX vs Peers
Repare Therapeutics Inc. (RPTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RPTX SEC Filings & Documents
Repare Therapeutics Inc. (RPTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when RPTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RPTX Frequently Asked Questions
Repare Therapeutics Inc. (RPTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Repare Therapeutics Inc.'s revenue?
Repare Therapeutics Inc. (RPTX) reported $11.9M in revenue for fiscal year 2024.
How fast is Repare Therapeutics Inc. growing?
Repare Therapeutics Inc. (RPTX) grew revenue by 4.6% over the past year. Growth has been modest.
Is RPTX profitable?
Repare Therapeutics Inc. (RPTX) reported a net loss of $72.2M for fiscal year 2024.
Dividend & Returns
What is RPTX's return on equity?
Repare Therapeutics Inc. (RPTX) has a return on equity (ROE) of -46.6%. Negative ROE indicates the company is unprofitable.
What is Repare Therapeutics Inc.'s free cash flow?
Repare Therapeutics Inc. (RPTX) had negative free cash flow of $70.1M in fiscal year 2024, likely due to heavy capital investments.